Xcout IntelArkgen Bioscions
Arkgen Bioscions is a South Korean immuno-oncology startup headquartered in Daejeon. The company recently raised a $6.67 million Series A funding round to advance its proprietary biotech research. It focuses on developing innovative biopharmaceutical treatments.
Subscribe to see Arkgen Bioscions’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Arkgen Bioscions at a glance
Arkgen Bioscions is a drug discovery company headquartered in South Korea. Its most recent funding round, Series A, raised $6.7M in July 2026. Xcout tracks 1 named person at Arkgen Bioscions, including Seungwon Lee (CEO).
Arkgen Bioscions leadership
- Seungwon LeeCEO
Arkgen Bioscions funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $6.7M | 14 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Arkgen Bioscions competitors
A few of Arkgen Bioscions's closest competitors — see the full list of competitors and alternatives →
Arch Oncology is a clinical-stage immuno-oncology company headquartered in Brisbane, California, with an additional scientific research laboratory in St. Louis, Missouri. The company develops antibody-based cancer therapies.
Coultreon Biopharma is a clinical-stage biotechnology company headquartered in Leuven, Belgium, focused on developing next-generation precision medicines for immunology and autoimmune diseases. Backed by substantial venture funding, the company advances innovative therapies.
Momotaro-Gene Inc. is a drug discovery company established in 2007 and headquartered in Okayama, Japan. The company focuses on pharmaceutical research and the development of next-generation cancer therapeutics.
Ahammune Biosciences is an India-based drug-discovery biotechnology company focused on developing small-molecule therapies for immune-mediated and inflammatory diseases. It serves pharmaceutical and healthcare markets by advancing novel immunomodulatory drug candidates toward clinical development.
OncoMyx Therapeutics, Inc. is a biotechnology company headquartered in Phoenix, Arizona, that develops innovative oncolytic immunotherapies to target and destroy tumors.
ARMO BioSciences is a late-stage immuno-oncology company that develops a pipeline of novel, proprietary product candidates designed to activate the immune system of cancer patients to recognize and eradicate tumors.
Get Arkgen Bioscions's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Arkgen Bioscions in Xcout Intel
- 1 named person with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access